Major Companies for Therapeutic Antibodies Drug Market: AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, Regeneron, Innovent, Hengrui Medicine.
Global Therapeutic Antibodies Drug Market Size was estimated at USD 971.7 million in 2022 and is projected to reach USD 1229.51049027256 million by 2028, exhibiting a CAGR of 4% during the forecast period.
Global Therapeutic Antibodies Drug Market Overview And Scope:
The Global Therapeutic Antibodies Drug Market Report 2024 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Therapeutic Antibodies Drug utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2024 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
This Market Research Report provides a comprehensive analysis of the global Therapeutic Antibodies Drug Market and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Therapeutic Antibodies Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Therapeutic Antibodies Drug market.
Global Therapeutic Antibodies Drug Market Segmentation
By Type, Therapeutic Antibodies Drug market has been segmented into:
Monoclonal Antibodies
Bi-Specific Antibodies Therapy
Antibody-drug Conjugates
Other
By Application, Therapeutic Antibodies Drug market has been segmented into:
Immune Diseases
Cancer
Other
Regional Analysis of Therapeutic Antibodies Drug Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Therapeutic Antibodies Drug Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Therapeutic Antibodies Drug market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Therapeutic Antibodies Drug market.
Major Companies Covered in Therapeutic Antibodies Drug market are:
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
Regeneron
Innovent
Hengrui Medicine
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Therapeutic Antibodies Drug Market by Type
5.1 Therapeutic Antibodies Drug Market Overview Snapshot and Growth Engine
5.2 Therapeutic Antibodies Drug Market Overview
5.3 Monoclonal Antibodies
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Monoclonal Antibodies: Geographic Segmentation
5.4 Bi-Specific Antibodies Therapy
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Bi-Specific Antibodies Therapy: Geographic Segmentation
5.5 Antibody-drug Conjugates
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Antibody-drug Conjugates: Geographic Segmentation
5.6 Other
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Other: Geographic Segmentation
Chapter 6: Therapeutic Antibodies Drug Market by Application
6.1 Therapeutic Antibodies Drug Market Overview Snapshot and Growth Engine
6.2 Therapeutic Antibodies Drug Market Overview
6.3 Immune Diseases
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Immune Diseases: Geographic Segmentation
6.4 Cancer
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Cancer: Geographic Segmentation
6.5 Other
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Therapeutic Antibodies Drug Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Therapeutic Antibodies Drug Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Therapeutic Antibodies Drug Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 ABBVIE
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 JOHNSON & JOHNSON
7.4 NOVARTIS
7.5 GILEAD SCIENCES
7.6 ROCHE
7.7 BRISTOL-MYERS SQUIBB
7.8 AMGEN
7.9 ASTRAZENECA
7.10 MERCK & CO
7.11 TAKEDA
7.12 MERCK KGAA
7.13 SEAGEN
7.14 ELI LILLY
7.15 ONO PHARMACEUTICAL
7.16 PFIZER
7.17 REGENERON
7.18 INNOVENT
7.19 HENGRUI MEDICINE
Chapter 8: Global Therapeutic Antibodies Drug Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Monoclonal Antibodies
8.2.2 Bi-Specific Antibodies Therapy
8.2.3 Antibody-drug Conjugates
8.2.4 Other
8.3 Historic and Forecasted Market Size By Application
8.3.1 Immune Diseases
8.3.2 Cancer
8.3.3 Other
Chapter 9: North America Therapeutic Antibodies Drug Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Monoclonal Antibodies
9.4.2 Bi-Specific Antibodies Therapy
9.4.3 Antibody-drug Conjugates
9.4.4 Other
9.5 Historic and Forecasted Market Size By Application
9.5.1 Immune Diseases
9.5.2 Cancer
9.5.3 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Therapeutic Antibodies Drug Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Monoclonal Antibodies
10.4.2 Bi-Specific Antibodies Therapy
10.4.3 Antibody-drug Conjugates
10.4.4 Other
10.5 Historic and Forecasted Market Size By Application
10.5.1 Immune Diseases
10.5.2 Cancer
10.5.3 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Therapeutic Antibodies Drug Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Monoclonal Antibodies
11.4.2 Bi-Specific Antibodies Therapy
11.4.3 Antibody-drug Conjugates
11.4.4 Other
11.5 Historic and Forecasted Market Size By Application
11.5.1 Immune Diseases
11.5.2 Cancer
11.5.3 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Therapeutic Antibodies Drug Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Monoclonal Antibodies
12.4.2 Bi-Specific Antibodies Therapy
12.4.3 Antibody-drug Conjugates
12.4.4 Other
12.5 Historic and Forecasted Market Size By Application
12.5.1 Immune Diseases
12.5.2 Cancer
12.5.3 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Therapeutic Antibodies Drug Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Monoclonal Antibodies
13.4.2 Bi-Specific Antibodies Therapy
13.4.3 Antibody-drug Conjugates
13.4.4 Other
13.5 Historic and Forecasted Market Size By Application
13.5.1 Immune Diseases
13.5.2 Cancer
13.5.3 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Therapeutic Antibodies Drug Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Monoclonal Antibodies
14.4.2 Bi-Specific Antibodies Therapy
14.4.3 Antibody-drug Conjugates
14.4.4 Other
14.5 Historic and Forecasted Market Size By Application
14.5.1 Immune Diseases
14.5.2 Cancer
14.5.3 Other
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Therapeutic Antibodies Drug Scope:
Report Data
|
Therapeutic Antibodies Drug Market
|
Therapeutic Antibodies Drug Market Size in 2022
|
USD 971.7 million
|
Therapeutic Antibodies Drug CAGR 2023 - 2030
|
4%
|
Therapeutic Antibodies Drug Base Year
|
2022
|
Therapeutic Antibodies Drug Forecast Data
|
2023 - 2030
|
Segments Covered
|
By Type, By Application, And by Regions
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
Key Companies Profiled
|
AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, Regeneron, Innovent, Hengrui Medicine.
|
Key Segments
|
By Type
Monoclonal Antibodies Bi-Specific Antibodies Therapy Antibody-drug Conjugates Other
By Applications
Immune Diseases Cancer Other
|